<DOC>
	<DOCNO>NCT00566241</DOCNO>
	<brief_summary>28 week pilot study examine efficacy recombinant human IGF-1 body weight composition adult cystic fibrosis .</brief_summary>
	<brief_title>IGF-1 Therapy Patients With Cystic Fibrosis</brief_title>
	<detailed_description>28 week , double blind , cross study determine efficacy rhIGF-1 body weight body composition patient cystic fibrosis .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Diagnosis cystic fibrosis proven either sweat chloride DNA analysis . Age &gt; = 18 yr. Tanner stage : Femake Breasts : 45 Male Genitalia : 45 Exclusion criterion : Hemoglobin A1C &gt; 8.5 % Diabetic retinopathy Obstructive sleep apnea Respiratory failure require mechanical ventilation . Status post pulmonary transplantation . Concurrent recent ( within past 6 month ) receipt human growth hormone . History adverse side effect growth hormone carbohydrate intolerance . Pregnancy attempt pregnancy . Women breast feeding . Sexually active woman refuse use incapable responsibly use reliable contraception . Proven non compliance medical regimen . Inability refusal take subcutaneous injection . Known allergy component IGFI preparation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Body weight</keyword>
	<keyword>Body composition</keyword>
	<keyword>Pulmonary function</keyword>
	<keyword>Carbohydrate tolerance</keyword>
</DOC>